Antigen Loss From Antibody-Coated Red Blood Cells

Transfusion Medicine Reviews

Volumn 23, Issue 3, 2009, Pages 189-204

  Zimring, James C ^a,b   Cadwell, Chantel M ^a,b   Spitalnik, Steven L ^a,b  

^a Center for Transfusion and Cellular Therapies   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BLOOD GROUP ANTIGEN; CD20 ANTIGEN; CHOLINERGIC RECEPTOR; CORTICOSTEROID; DECAY ACCELERATING FACTOR; DUFFY BINDING PROTEIN; EPITOPE; ERYTHROCYTE ANTIBODY; ERYTHROCYTE ANTIGEN; FC RECEPTOR; GLYCOPHORIN C; GLYCOPROTEIN VI; IMMUNOGLOBULIN G; LEUKOCYTE ANTIGEN; LYSOZYME; RITUXIMAB; THROMBOCYTE ANTIGEN; TUMOR ANTIGEN;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGENIC MODULATION; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; BACTERIAL INFECTION; BLOOD ANALYSIS; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUP KELL SYSTEM; BLOOD GROUP KIDD SYSTEM; BLOOD GROUP RHESUS SYSTEM; BLOOD GROUP TYPING; BLOOD TRANSFUSION; CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; COOMBS TEST; CYTOLOGY; DISEASE ASSOCIATION; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; EXPERIMENTAL MODEL; GLYCOSYLATION; HEMOLYSIS; HUMAN; IMMUNOGENETICS; IN VITRO STUDY; MOLECULAR MECHANICS; MYASTHENIA GRAVIS; NONHUMAN; PROTEUS MIRABILIS; SIDE EFFECT; SPLENECTOMY; STREPTOCOCCUS GROUP D;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGEN-ANTIBODY REACTIONS; ANTIGENIC MODULATION; ANTIGENS, SURFACE; AUTOIMMUNITY; DISEASE; ERYTHROCYTES; HUMANS; IMMUNE SYSTEM; MODELS, ANIMAL;

EID: 66949174062     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2009.03.002     Document Type: Article

References (62)

1. Reid M.E., and Lomas-Francis C. The blood group antigen facts book. 2nd ed. (2004), Elsevier Academic Press, Amsterdam
2. Bosco A.M., Xenocostas A., Kinney J., et al. An auto-anti-Kpb IgM that simulates antigen-suppression. Transfusion 49 (2009) 750-756
3. Seyfried H., Gorska B., Maj S., et al. Apparent depression of antigens of the Kell blood group system associated with autoimmune acquired haemolytic anaemia. Vox Sang 23 (1972) 528-536
4. Beck M.L., Marsh W.L., Pierce S.R., et al. Auto anti-Kpb associated with weakened antigenicity in the Kell blood group system: A second example. Transfusion 19 (1979) 197-202
5. Brendel W.L., Issitt P.D., Moore R.E., et al. Temporary reduction of red cell Kell system antigen expression and transient production of anti-Kpb in a surgical patient. Biotest Bull 2 (1985) 201-206
6. Marsh W.L., Oyen R., Alicea E., et al. Autoimmune hemolytic anemia and the Kell blood groups. Am J Hematol 7 (1979) 155-162
7. Vengelen-Tyler V., Gonzalez B., Garratty G., et al. Acquired loss of red cell Kell antigens. Br J Haematol 65 (1987) 231-234
8. Williamson L.M., Poole J., Redman C., et al. Transient loss of proteins carrying Kell and Lutheran red cell antigens during consecutive relapses of autoimmune thrombocytopenia. Br J Haematol 87 (1994) 805-812
9. Koscielak J. Session on blood group substances and red cell membrane receptors. Vox Sang 39 (1980) 289
10. van't Veer M.B., van Wieringen P.M., van Leeuwen I., et al. A negative direct antiglobulin test with strong IgG red cell autoantibodies present in the serum of a patient with autoimmune haemolytic anaemia. Br J Haematol 49 (1981) 383-386
11. Issitt P.D., Gruppo R.A., Wilkinson S.L., et al. Atypical presentation of acute phase, antibody-induced haemolytic anaemia in an infant. Br J Haematol 52 (1982) 537-543
12. Issitt P.D., Wilkinson S.L., and Gruppo R.A. Depression of Rh antigen expression in antibody-induced haemolytic anaemia. Br J Haematol 53 (1983) 688
13. Ganly P.S., Laffan M.A., Owen I., et al. Auto-anti-Jka in Evans' syndrome with negative direct antiglobulin test. Br J Haematol 69 (1988) 537-539
14. Issitt P.D., Obarski G., Hartnett P.L., et al. Temporary suppression of Kidd system antigen expression accompanied by transient production of anti-Jk3. Transfusion 30 (1990) 46-50
15. Powers A., Mohammed M., Uhl L., et al. Apparent nonhemolytic alloantibody-induced red-cell antigen loss from transfused erythrocytes. Blood 109 (2007) 15
16. Beattie K.M., and Sigmund K.E. A Ge-like autoantibody in the serum of a patient receiving gold therapy for rheumatoid arthritis. Transfusion 27 (1987) 54-57
17. Daniels G.L., Reid M.E., Anstee D.J., et al. Transient reduction in erythrocyte membrane sialoglycoprotein beta associated with the presence of elliptocytes. Br J Haematol 70 (1988) 477-481
18. Chown B., Kaita H., Lowen B., et al. Transient production of anti-LW by LW-positive people. Transfusion 11 (1971) 220-222
19. Giles C.M., and Lundsgaard A. A complex serological investigation involving LW. Vox Sang 13 (1967) 406-416
20. Perkins H.A., McIlroy M., Swanson J., et al. Transient LW-negative red blood cells and anti-LW in a patient with Hodgkin's disease. Vox Sang 33 (1977) 299-303
21. Mannessier L., Rouger P., Johnson C.L., et al. Acquired loss of red-cell Wj antigen in a patient with Hodgkin's disease. Vox Sang 50 (1986) 240-244
22. Banks J., Poole J., Prowse C., et al. Transient loss of Cromer antigens and anti-IFC in a patient with chronic lymphatic leukaemia. Vox Sang 87 (2004) S37-S38
23. Matthes T., Tullen E., Poole J., et al. Acquired and transient RBC CD55 deficiency (Inab phenotype) and anti-IFC. Transfusion 42 (2002) 1448-1457
24. Yazer M.H., Judd W.J., Davenport R.D., et al. Case report and literature review: Transient Inab phenotype and an agglutinating anti-IFC in a patient with a gastrointestinal problem. Transfusion 46 (2006) 1537-1542
25. Cadwell C.M., and Zimring J.C. Cross-linking induces non-haemolytic antigen-loss from transfused red blood cells: A potential role for rheumatoid factor. Vox Sang 95 (2008) 159-162
26. Mack D.A., Beum P.V., Lindorfer M.A., et al. The shaving reaction is facilitated through trogocytosis: concerted transfer of both rituximab (RTX) and membrane dye PKH26 from B lymphocytes to macrophages is demonstrable by flow cytometry, fluorescence microscopy, and high resolution digital imaging in a flow cytometric environment. Blood 108 (2006) 594a
27. Poole J., Reid M.E., Banks J., et al. Serological and immunochemical specificity of a human autoanti-Gerbich-like antibody. Vox Sang 58 (1990) 287-291
28. Beum P.V., Kennedy A.D., Li Y., et al. Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab. J Immunol Methods 294 (2004) 37-42
29. b red cell antigen and gram-negative organisms (abstract). Transfusion 19 (1979) 663
30. McGinniss M.H., MacLowry J.D., and Holland P.V. Acquisition of K:1-like antigen during terminal sepsis. Transfusion 24 (1984) 28-30
31. Miescher S., Spycher M.O., Amstutz H., et al. A single recombinant anti-RhD IgG prevents RhD immunization: Association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes. Blood 103 (2004) 40284035
32. Schirmer D.A., Song S.C., Baliff J.P., et al. Mouse models of IgG- and IgM-mediated hemolysis. Blood 109 (2007) 3099-3107
33. Campbell-Lee S.A., Liu J., Velliquette R.W., et al. The production of red blood cell alloantibodies in mice transfused with blood from transgenic Fyb-expressing mice. Transfusion 46 (2006) 1682-1688
34. Zimring J.C., Hair G.A., Chadwick T.E., et al. Nonhemolytic antibody-induced loss of erythrocyte surface antigen. Blood 106 (2005) 1105-1112
35. Zimring J.C., Cadwell C.M., Chadwick T.E., et al. Nonhemolytic antigen loss from red blood cells requires cooperative binding of multiple antibodies recognizing different epitopes. Blood 110 (2007) 2201-2208
36. Fearon D.T. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med 152 (1980) 20-30
37. Nelson Jr. R.A. The immune-adherence phenomenon; a hypothetical role of erythrocytes in defence against bacteria and viruses. Proc R Soc Med 49 (1956) 55-58
38. Nelson Jr. R.A. The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science 118 (1953) 733-737
39. Cosio F.G., Shen X.P., Birmingham D.J., et al. Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates. J Immunol 145 (1990) 4198-4206
40. Cornacoff J.B., Hebert L.A., Smead W.L., et al. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest 71 (1983) 236-247
41. Davies K.A., Hird V., Stewart S., et al. A study of in vivo immune complex formation and clearance in man. J Immunol 144 (1990) 4613-4620
42. Nardin A., Lindorfer M.A., and Taylor R.P. How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocytic cells?. Mol Immunol 36 (1999) 827-835
43. Moll S., Miot S., Sadallah S., et al. No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int 59 (2001) 160-168
44. Bertram J.H., Gill P.S., Levine A.M., et al. Monoclonal antibody T101 in T cell malignancies: A clinical, pharmacokinetic, and immunologic correlation. Blood 68 (1986) 752-761
45. Letvin N.L., Ritz J., Guida L.J., et al. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: I. Effects of anti-T11 antibodies on the circulating T cell pool. Blood 66 (1985) 961-966
46. Miller R.A., Maloney D.G., McKillop J., et al. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 58 (1981) 78-86
47. Shawler D.L., Johnson D.E., McCallister T.J., et al. Mechanisms of human CD5 modulation and capping induced by murine monoclonal antibody T101. Clin Immunol Immunopath 47 (1988) 219-229
48. Shawler D.L., Miceli M.C., Wormsley S.B., et al. Induction of in vitro and in vivo antigenic modulation by the anti-human T-cell monoclonal antibody T101. Cancer Res 44 (1984) 5921-5927
49. Kennedy A.D., Beum P.V., Solga M.D., et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172 (2004) 3280-3288
50. Li Y., Williams M.E., Cousar J.B., et al. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol 179 (2007) 4263-4271
51. Beum P.V., Kennedy A.D., Williams M.E., et al. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 176 (2006) 2600-2609
52. Beum P.V., Lindorfer M.A., and Taylor R.P. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 181 (2008) 2916-2924
53. Beum P.V., Mack D.A., Pawluczkowycz A.W., et al. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 181 (2008) 8120-8132
54. Griffin Jr. F.M., Griffin J.A., and Silverstein S.C. Studies on the mechanism of phagocytosis. II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone marrow-derived lymphocytes. J Exp Med 144 (1976) 788-809
55. Boylan B., Chen H., Rathore V., et al. Anti-GPVI-associated ITP: An acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood 104 (2004) 1350-1355
56. Massberg S., Gawaz M., Gruner S., et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 197 (2003) 41-49
57. Nieswandt B., Schulte V., Bergmeier W., et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 193 (2001) 459-469
58. Schulte V., Rabie T., Prostredna M., et al. Targeting of the collagen-binding site on glycoprotein VI is not essential for in vivo depletion of the receptor. Blood 101 (2003) 3948-3952
59. Loutrari H., Kokla A., and Tzartos S.J. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol 22 (1992) 2449-2452
60. Sophianos D., and Tzartos S.J. Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against antigenic modulation caused by myasthenic sera. J Autoimmun 2 (1989) 777-789
61. Tzartos S.J., Sophianos D., and Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J Immunol 134 (1985) 2343-2349
62. Kao I., and Drachman D.B. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science 196 (1977) 527-529